ESMO Congress 2019
24 Sep 2019
This Friday marks the beginning of the ESMO Congress 2019, where MRC Clinical Trials Unit at UCL will be presenting results from prostate and kidney cancer trials.
The ESMO Congress brings together a large number of oncology professionals from across Europe. It will take place from Friday 27 September - Tuesday 1 Oct in Barcelona, Spain.
Details of the MRC CTU at UCL presentations taking place at ESMO 2019 are shown below.
| Day | Session (local time) | Session Type | Title | Author(s) | Location |
| 27.09.2019 | 14:00 - 15:30 | Proffered Paper session | 844O - Docetaxel for hormone-naïve prostate cancer: results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden (ID 2348) | N. Clarke et al. | Sevilla Auditorium (Hall 2) |
| 27.09.2019 | 14:00 - 15:30 | Proffered Paper session | LBA49_PR - Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): First Results from the RADICALS RT Randomised Controlled Trial (RCT) [NCT00541047] | C. Parker et al. | Sevilla Auditorium (Hall 2) |
| 27.09.2019 | 14:00 - 15:30 | Proffered Paper session | LBA48_PR - Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis (ID 2508) | C. Vale et al. | Sevilla Auditorium (Hall 2) |
| 28.09.2019 | 14:45 - 16:00 | Proffered Paper session | LBA56 - Primary Efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: an international, randomised double-blind phase III trial led by the MRC CTU at UCL (ID 2483) | T. Eisen et al. | Sevilla Auditorium (Hall 2) |
| 29.09.2019 | 08:30 - 09:45 | Poster Discussion session | 855PD - Docetaxel for hormone-naïve prostate cancer (PCa): results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial (NCT00268476) (ID 2495) | N. James et al. | Malaga Auditorium (Hall 5) |
| 29.09.2019 | 08:30 - 09:46 | Poster Discussion session | 850PD - Benefit of prostate radiotherapy for patients with lymph node only or < 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site and number in the STAMPEDE “M1|RT comparison” (ID 1199) | S. Adnan Ali et al. | Malaga Auditorium (Hall 5) |
| 30.09.2019 | 12:00 - 13:00 | Poster Display session | 857P - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial (ID 2134) | J. E. Brown et al. | Poster Area (Hall 4) |
| 30.09.2019 | 12:00 - 13:00 | Poster Display session | 862P - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE (ID 1500) | H. P. Mintz et al. | Poster Area (Hall 4) |